Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Therapy Overview: Sequencing Agents in Patients With Metastatic CRPC

August 9th 2022

A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.

FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

August 5th 2022

The FDA has approved darolutamide tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders

August 5th 2022

Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.

REGN5678 Plus Cemiplimab Demonstrates Early Activity in mCRPC

August 3rd 2022

The novel PSMAxCD38 costimulatory bispecific antibody REGN5678 has shown encouraging efficacy in combination with cemiplimab in patients with advanced metastatic castration-resistant prostate cancer, according to preliminary findings from an ongoing phase 1/2 trial (NCT03972657).

Pembrolizumab Plus Chemotherapy Fails to Improve OS, Radiographic PFS in mCRPC

August 3rd 2022

Pembrolizumab plus docetaxel failed to elicit a statistically significant improvement in overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, missing the coprimary end points of the phase 3 KEYNOTE-921 trial.

Retrospective Analysis Highlights Disparities in Germline Testing in Prostate Cancer

August 2nd 2022

Carrie Horton, MS, CGC, discusses how the findings from a retrospective analysis of germline testing rates among racially diverse groups of men with prostate cancer will guide future research and influence the steps community oncologists can take to increase testing rates.

Metastatic Castration-Resistant Prostate Cancer: Optimal Imaging Strategies

August 2nd 2022

Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.

Clinical Scenario 3: A 76-Year-Old With Metastatic CRPC

August 2nd 2022

Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.

SHR3680 Plus ADT Improves Survival Vs Bicalutamide/ADT in High-Volume mHSPC

July 27th 2022

The addition of SHR3680 to androgen deprivation therapy significantly improved radiographic progression-free survival and overall survival compared with bicalutamide plus ADT in patients with high-volume, metastatic hormone-sensitive prostate cancer, according to data from the phase 3 CHART trial.

Addressing Unmet Needs in Nonmetastatic CRPC

July 26th 2022

Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.

Selecting Among Available AR Inhibitors in Nonmetastatic CPRC

July 26th 2022

A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.

Dr. Wise on Unmet Needs in the Standard of Care in Prostate Cancer

July 25th 2022

David R. Wise, MD, PhD, discusses unmet needs in the standard of care in prostate cancer.

Optimizing Management of nmCRPC: Patient Monitoring and Initiating Therapy

July 19th 2022

Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.

Clinical Scenario 2: A 64-Year-Old Man With nmCRPC

July 19th 2022

Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.

ModraDoc006 Plus Ritonavir Shows Favorable Safety, Comparable Efficacy to IV Docetaxel in mCRPC

July 14th 2022

The combination of ModraDoc006—a novel, oral tablet formulation of docetaxel—and ritonavir produced comparable response rates and radiographic progression-free survival to that achieved with intravenous docetaxel in patients with metastatic castration-resistant prostate cancer.

Management of HCC: Advances in Biomarkers and Screening

July 13th 2022

A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.

Dr. Sandhu on Findings with Niraparib in Metastatic Prostate Cancer

July 12th 2022

Shahneen Sandhu, MD, discusses findings with niraparib in metastatic prostate cancer from the phase 3 MAGNITUDE trial.

FOR46 Shows Early Antitumor Activity in Metastatic Castration-Resistant Prostate Cancer

July 12th 2022

The CD46-targeted antibody-drug conjugate FOR46 demonstrated encouraging evidence of antitumor activity in patients with metastatic castration-resistant prostate cancer with a safety profile that proved to be similar to other monomethyl auristatin E–based ADCs, according to data from a phase 1a/1b trial.

Improving Patient Monitoring in the Setting of Metastatic HSPC

July 12th 2022

Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.

Clinical Trial Data in Metastatic HSPC From the ASCO 2022 Annual Meeting

July 12th 2022

Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.